导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.52% | 4170/4773 |
| 近一周 | -4.01% | 4779/5462 |
| 近一月 | -2.73% | 1377/5421 |
| 近一季 | 0.95% | 602/5209 |
| 近半年 | -15.41% | 3986/4920 |
| 近一年 | -25.11% | 4079/4366 |
| 近两年 | -0.78% | 2895/2954 |
| 近三年 | -28.69% | 2202/2253 |
| 成立以来 | 232.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.95% 3980/4961 |
-17.15% 4760/5312 |
- - |
- - |
| 2025 | -2.81% 3342/4813 |
-0.49% 2275/3635 |
-2.26% 3333/4076 |
6.53% 3522/4524 |
-6.20% 3678/4813 |
| 2024 | -4.71% 2246/3463 |
0.97% 914/2808 |
-9.70% 2388/3014 |
15.24% 1778/3129 |
-9.32% 2919/3463 |
| 2023 | -16.45% 1683/2656 |
2.56% 1336/2280 |
-12.64% 2188/2385 |
-0.81% 449/2515 |
-5.99% 1583/2655 |
| 2022 | -12.46% 287/2207 |
-16.62% 1142/1919 |
15.26% 177/2016 |
-9.16% 249/2113 |
0.28% 1518/2208 |
| 2021 | -4.40% 949/1822 |
-5.69% 946/1255 |
4.39% 893/1330 |
-9.98% 1202/1466 |
7.86% 173/1822 |
| 2020 | 75.23% 55/1250 |
1.32% 147/1028 |
20.18% 281/1067 |
17.77% 99/1164 |
22.19% 48/1184 |
| 2019 | 64.25% 42/1092 |
42.62% 38/754 |
10.39% 6/804 |
1.30% 415/850 |
2.99% 847/918 |
| 2018 | -23.61% 292/834 |
- - |
- - |
- - |
-16.01% 621/691 |
| 2017 | 55.89% 7/714 |
- - |
- - |
- - |
- - |
| 2016 | 2.20% 85/605 |
- - |
- - |
- - |
- - |
| 2015 | 23.97% 97/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 嘉实中证主要消费ETF VS. 长安沪深300非周期A(740101) |